Donald Mager, BS ’91, PharmD ’00 and PhD ’02, professor and vice chair, Department of Pharmaceutical Sciences, has been appointed a Fellow of the International Pharmaceutical Federation (FIP).
Diclofenac and other NSAIDs may limit the passage of narcolepsy medication and illicit party drug GHB to the brain, decreasing the potential for fatal overdose, UB researchers find.
Mitochondrial dysfunction in vulnerable neurons in the brain can be an early indicator of Alzheimer’s disease, yet the underlying molecular mechanisms remain misunderstood.
The UB program offers students a unique opportunity to engage in research and training to combat disease, as well as help develop a pipeline of research leaders focused on therapeutic individualization and optimization of patient care.
Using a new class of drugs developed at UB, researchers aim to prevent anticancer toxins from harming healthy tissue. The work is supported by a $1.8 million grant from the National Cancer Institute.
“In an era of increased medical costs, this type of patient-centered treatment will be integral to decreasing disparities in health outcomes," says Nicholas Smith, PhD, assistant professor and project leader .
University at Buffalo School of Pharmacy and Pharmaceutical Sciences faculty and staff participated in this year’s virtual American Association of Colleges of Pharmacy (AACP) Annual Meeting, held July 19-22. 2021.
Fred Doloresco, PharmD, MS, Director of Assessment and Clinical Associate Professor, has been selected to participate in the American Association of Colleges of Pharmacy (AACP) 2021-2022 Academic Leadership Fellows Program.
